Baudax Bio

Baudax Bio, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amplify Energy Corp.

Calyxt

ReShape Lifesciences

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

5 Penny Stocks Insiders Are Buying

Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.

Do Options Traders Know Something About Baudax Bio (BXRX) Stock We Don't?

The shares of Baudax Bio Inc (NASDAQ: BXRX) increased by over 45% pre-market. This is why it happened.

Baudax Bio Shares Increase Over 45% Pre-Market: Why It Happened

Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q2 2021 Results - Earnings Call Transcript

Shares of Baudax Bio (NASDAQ:BXRX) rose 0.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 87.79% year over year to ($0.21), which missed the estimate of ($0.20).

Baudax Bio: Q2 Earnings Insights

Total Number of ANJESO ® Vials Sold to End-Users in the Second Quarter 2021 Match Total Vials Sold for the Full Year 2020

Baudax Bio Reports Second Quarter 2021 Financial Results and Highlights

Special Meeting to be reconvened on August 11, 2021 solely with respect to Proposal 1 Special Meeting to be reconvened on August 11, 2021 solely with respect to Proposal 1

Baudax Bio Announces Date of Reconvened Special Meeting

MALVERN, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021. Baudax Bio's management team will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 5, 2021 to discuss the financial results and recent operational highlights.

Baudax Bio to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

MALVERN, Pa., July 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Glass Lewis & Co., a leading proxy advisory firm, has recommended that Baudax Bio shareholders vote “FOR” Item 1 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on June 14, 2021 in connection with its Special Meeting, which seeks to amend Baudax Bio's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Special Meeting will be held on July 13, 2021 at 9:00 a.m. ET and will be held virtually at www.virtualshareholdermeeting.com/BXRX2021.

Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends Baudax Bio Shareholders Vote “For” the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders

MALVERN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Institutional Shareholder Services, Inc. (“ISS”), the leading global independent proxy advisory firm, has recommended that Baudax Bio shareholders vote “FOR” Item 1 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on June 14, 2021 in connection with its Special Meeting, which seeks to amend Baudax Bio's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Special Meeting will be held on July 13, 2021 at 9:00 a.m. ET and will be held virtually at www.virtualshareholdermeeting.com/BXRX2021.

Leading Independent Advisory Firm Institutional Shareholder Services, Inc. Recommends Baudax Bio Shareholders Vote “For” the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders

Special meeting to be held virtually on July 13, 2021, at 9:00 a.m. Eastern Time Special meeting to be held virtually on July 13, 2021, at 9:00 a.m. Eastern Time

Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced Gerri Henwood, the Company's President and Chief Executive Officer, will participate in a fireside chat virtually at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 4:00 p.m. ET.

Baudax Bio to Participate in the JMP Securities Life Sciences Conference

MALVERN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that ANJESO® (meloxicam) injection has achieved approvals at over 100 formularies across the U.S. in under one year of commercialization. ANJESO's presence on formularies is expected to drive usage through regular availability at both hospitals and ambulatory care centers covered by these formularies.

Baudax Bio's ANJESO® Achieves Formulary Listing at Over 100 Institutions in Less Than One Year on the Market

MALVERN, Pa., May 31, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 14,028,520 shares of common stock and warrants to purchase up to an aggregate of 14,028,520 shares of common stock at a purchase price of $0.85 per share and accompanying warrant in a registered direct offering. The warrants have an exercise price of $0.90 per share, will become exercisable upon the later of (i) the six-month anniversary of the closing date of the offering, and (ii) the date of approval by the Baudax Bio shareholders of an increase in the number of Baudax Bio's authorized shares of common stock, and will expire on December 1, 2026. The closing of the offering is expected to occur on or about June 1, 2021, subject to the satisfaction of customary closing conditions.

Baudax Bio Announces $11.9 Million Registered Direct Offering

MALVERN, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that it has determined to withdraw from shareholder consideration Proposal 3 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on March 11, 2021, with respect to an increase in the number of shares of common stock authorized for issuance under the Company's Amended and Restated Certificate of Incorporation. As a result, the Company has determined to cancel the reconvening of its annual meeting of shareholders for the consideration of Proposal 3, which was previously adjourned solely with respect to Proposal 3 to 10:00 a.m. Eastern Time on June 3, 2021. All other items set forth in the Company's Definitive Proxy Statement were submitted to shareholder vote at the Company's annual meeting of shareholders on April 7, 2021.

Baudax Bio Announces the Cancellation of Adjourned Portion of Annual Shareholder Meeting

MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Institutional Shareholder Services, Inc. (ISS), the leading global independent proxy advisory firm, has recommended that Baudax Bio shareholders vote "FOR" Proposal 3, which seeks to amend the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Annual Meeting is expected to resume with respect to Proposal 3 on June 3, 2021 at 10:00 a.m. ET and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2021.

Leading Independent Advisory Firm Institutional Shareholder Services, Inc. Recommends Baudax Bio Shareholders Vote "For" the Proposed Additional Authorized Shares

MALVERN, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that Glass Lewis & Co. has recommended that Baudax Bio shareholders vote "FOR" Proposal 3, which seeks to amend the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Annual Meeting is expected to resume with respect to Proposal 3 on June 3, 2021 at 10:00 a.m. ET and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2021.

Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends Baudax Bio Shareholders Vote "For" The Additional Authorized Shares

Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q1 2021 Results - Earnings Call Transcript

ANJESO ® Demonstrates Continued Progress with Launch; Growth in End-User Unit Sales Increased 40% in Q1 compared to Q4'20

Baudax Bio Reports First Quarter 2021 Financial Results

MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on developing and commercializing innovative products for acute care settings, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021. Baudax Bio's management team will host a conference call and webcast at 8:00 a.m. ET on Wednesday, May 5, 2021 to discuss the financial results and recent operational highlights.

Baudax Bio to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 5, 2021

Baudax Bio Inc (NASDAQ: BXRX) has announced the online publication of Phase 3b study data highlighting the safety and efficacy of preoperative Anjeso (meloxicam) injection in patients undergoing unilateral total knee arthroplasty (TKA) when used within a multimodal analgesic regimen in the peer-reviewed medical journal Pain Medicine. Anjeso is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.

Baudax Bio's Preoperative Med Associated With Pain Reduction, Lower Opioids Use In Patients After Knee Replacement

Investors need to pay close attention to Baudax (BXRX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Baudax (BXRX) Stock?

Annual Meeting to be adjourned solely with respect to Proposal 3 Annual Meeting to be adjourned solely with respect to Proposal 3

Baudax Bio Announces Partial Adjournment of Annual Meeting of Shareholders

MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President and Chief Executive Officer, will participate in a fireside chat at the virtual Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021 at 9:20 a.m. ET.

Baudax Bio to Participate at the Oppenheimer 31st Annual Healthcare Conference

BXRX is a currently discounted analgesia company that suffered from reduced demand due to COVID-19 pressure on elective surgeries. The company currently has an FDA-approved post-op analgesic that is favored by anesthesiologists, as well as a focused pipeline that could push it to the forefront of non-opioid analgesia companies.

News for Baudax Bio Stock (BXRX)